Barbieri, Christopher

Publications

Sort by

Co-Author Network

selected publications

Prostate cancer genetic alterations in Hispanic men. The Prostate. 2023 Academic Article GET IT
Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis. European urology oncology. 2023 Review GET IT
SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic acids research. 2023 Academic Article GET IT
Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv : the preprint server for biology. 2023 Article GET IT
JAK inhibition shows two faces in prostate cancer. Nature cancer. 2022 Comment GET IT
Times cited: 1
Race and prostate cancer: genomic landscape. Nature reviews. Urology. 2022 Review GET IT
Times cited: 6
Impact of Left-Digit Age Bias in the Treatment of Localized Prostate Cancer. The Journal of urology. 2022 Academic Article GET IT
Times cited: 1
Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 10
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. NEJM evidence. 2022 Academic Article GET IT
Times cited: 125
A multidisciplinary approach to optimize primary prostate cancer biobanking. Urologic oncology. 2022 Academic Article GET IT
Times cited: 1
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI insight. 2022 Academic Article GET IT
Times cited: 3
Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy. Advances in radiation oncology. 2022 Academic Article GET IT
Times cited: 1
Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022 Academic Article GET IT
Times cited: 3
G3BP1 inhibits Cul3^SPOP to amplify AR signaling and promote prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 6
Race and Genetic Alterations in Prostate Cancer. JCO precision oncology. 2021 Letter GET IT
Editorial Comment. The Journal of urology. 2021 Editorial Article GET IT
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell reports. 2021 Academic Article GET IT
Times cited: 9
Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. Journal of vascular and interventional radiology : JVIR. 2021 Letter GET IT
Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer. Frontiers in oncology. 2021 Review GET IT
Times cited: 987
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. The Journal of clinical investigation. 2021 Academic Article GET IT
Times cited: 11
Three-dimensional prostate CT segmentation through fine-tuning of a pre-trained neural network using no reference labeling. Proceedings of SPIE--the International Society for Optical Engineering. 2021 Academic Article GET IT
Times cited: 1
Tumor size and genomic risk in localized prostate cancer. Urologic oncology. 2021 Academic Article GET IT
Times cited: 2
Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts. The Journal of urology. 2021 Editorial Article GET IT
Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European urology open science. 2020 Academic Article GET IT
Times cited: 6
Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020 Article GET IT
Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. JAMA network open. 2020 Academic Article GET IT
Times cited: 9
Editorial Comment. The Journal of urology. 2020 Comment GET IT
Active Surveillance for Men with Intermediate Risk Prostate Cancer. The Journal of urology. 2020 Academic Article GET IT
Times cited: 11
Patient injuries and malfunctions associated with robotic prostatectomy: review of the manufacturer and user facility device experience database. Journal of robotic surgery. 2020 Academic Article GET IT
Times cited: 2
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?. European urology. 2020 Editorial Article GET IT
Times cited: 2
Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nature communications. 2020 Academic Article GET IT
Times cited: 20
Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urologic oncology. 2020 Academic Article GET IT
Times cited: 6
Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. JAMA network open. 2020 Academic Article GET IT
Times cited: 45
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Translational oncology. 2019 Academic Article GET IT
Times cited: 20
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation. Nature immunology. 2019 Academic Article GET IT
Times cited: 30
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 10
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 84
Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2019 Article GET IT
Times cited: 5
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019 Academic Article GET IT
Times cited: 107
The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. The Journal of urology. 2019 Academic Article GET IT
Times cited: 2
Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. The Journal of pathology. 2019 Academic Article GET IT
Times cited: 31
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer cell. 2019 Article GET IT
Times cited: 17
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 46
Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility. European urology. 2019 Editorial Article GET IT
Times cited: 2
Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates. The journal of sexual medicine. 2018 Academic Article GET IT
Times cited: 3
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular cancer research : MCR. 2018 Academic Article GET IT
Times cited: 32
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 80
Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy". Urologic oncology. 2018 Review GET IT
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 29
Molecular Subtypes of Prostate Cancer. Current oncology reports. 2018 Review GET IT
Times cited: 67
The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2018 Academic Article GET IT
Times cited: 458
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. The Journal of clinical investigation. 2017 Academic Article GET IT
Times cited: 22
The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. Urology. 2017 Academic Article GET IT
Times cited: 114
Vasectomy and Risk of Prostate Cancer in a Screening Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017 Academic Article GET IT
Times cited: 8
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of translational medicine. 2017 Academic Article GET IT
Times cited: 5
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature medicine. 2017 Academic Article GET IT
Times cited: 198
Molecular alterations in prostate cancer and association with MRI features. Prostate cancer and prostatic diseases. 2017 Academic Article GET IT
Times cited: 13
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 2017 Academic Article GET IT
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. European urology. 2017 Academic Article GET IT
Times cited: 15
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer cell. 2017 Academic Article GET IT
Times cited: 130
Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. The Journal of urology. 2017 Academic Article GET IT
Times cited: 15
Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. The Journal of urology. 2016 Academic Article GET IT
Times cited: 18
DNA Repair in Prostate Cancer: Biology and Clinical Implications. European urology. 2016 Review GET IT
Times cited: 157
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European urology. 2016 Review GET IT
Times cited: 52
Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. BJU international. 2016 Academic Article GET IT
Times cited: 12
Editorial Comment. The Journal of urology. 2016 Comment GET IT
Lethal Prostate Cancer in the PLCO Cancer Screening Trial. European urology. 2016 Academic Article GET IT
Times cited: 7
Molecular subtyping of prostate cancer. Current opinion in urology. 2016 Review GET IT
Times cited: 33
Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. The Journal of urology. 2016 Academic Article GET IT
Times cited: 43
Clinical variability and molecular heterogeneity in prostate cancer. Asian journal of andrology. 2016 Review GET IT
Times cited: 82
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia. European urology. 2015 Editorial Article GET IT
Times cited: 7
The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Academic Article GET IT
Times cited: 1945
Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial. JAMA oncology. 2015 Letter GET IT
Times cited: 10
SPOP mutation leads to genomic instability in prostate cancer. eLife. 2015 Academic Article GET IT
Times cited: 129
Reprint of: The prostate cancer genome: Perspectives and potential. Urologic oncology. 2015 Review GET IT
Times cited: 7
Genomic rearrangements in prostate cancer. Current opinion in urology. 2015 Review GET IT
Times cited: 25
Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. The Prostate. 2014 Review GET IT
Times cited: 12
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 2014 Academic Article GET IT
Times cited: 76
Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 120
Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Advances in urology. 2014 Academic Article GET IT
Times cited: 28
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014 Academic Article GET IT
Times cited: 22
The lethal clone in prostate cancer: redefining the index. European urology. 2014 Comment GET IT
Times cited: 28
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (New York, N.Y.). 2014 Academic Article GET IT
Times cited: 114
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 80
The prostate cancer genome: perspectives and potential. Urologic oncology. 2013 Review GET IT
Times cited: 48
Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456. The Journal of pathology. 2013 Letter GET IT
Times cited: 1
Evolution of novel biomarkers for detection of prostate cancer. The Journal of urology. 2013 Editorial Article GET IT
Times cited: 8
Molecular characterization of prostate cancer following androgen deprivation: the devil in the details. European urology. 2013 Editorial Article GET IT
Times cited: 3
The mutational landscape of prostate cancer. European urology. 2013 Review GET IT
Times cited: 149
Punctuated evolution of prostate cancer genomes. Cell. 2013 Academic Article GET IT
Times cited: 906
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 184
Deletion or underexpression of the Y-chromosome genes CDY2 and HSFY is associated with maturation arrest in American men with nonobstructive azoospermia. Asian journal of andrology. 2012 Academic Article GET IT
Times cited: 26
Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2012 Academic Article GET IT
Times cited: 24
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics. 2012 Academic Article GET IT
Times cited: 1144
Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology. 2012 Review GET IT
Times cited: 52
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. The Journal of urology. 2011 Academic Article GET IT
Times cited: 10
Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. BJU international. 2011 Academic Article GET IT
Times cited: 24
Tissue-based molecular markers for bladder cancer. Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2010 Review GET IT
Times cited: 10
Ureteroileal anastomosis with intraluminal visualization: technique and outcomes. Urology. 2010 Academic Article GET IT
Times cited: 6
DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Developmental biology. 2009 Academic Article GET IT
Times cited: 11
Association of procedure volume with radical cystectomy outcomes in a nationwide database. The Journal of urology. 2007 Academic Article GET IT
Times cited: 103
Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer research. 2006 Academic Article GET IT
Times cited: 203
The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophysical journal. 2006 Academic Article GET IT
Times cited: 60
p63 and epithelial biology. Experimental cell research. 2006 Review GET IT
Times cited: 106
Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell cycle (Georgetown, Tex.). 2005 Academic Article GET IT
Times cited: 62
p53 family members: similar biochemistry, different biology. Cancer biology & therapy. 2005 Comment GET IT
Times cited: 4
IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer research. 2005 Academic Article GET IT
Times cited: 72
Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 68
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. The Laryngoscope. 2003 Academic Article GET IT
Times cited: 50

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer awarded by National Cancer Institute Principal Investigator 2018 - 2025
Collaborative genomic alterations and transcriptional control in prostate cancer awarded by National Cancer Institute Principal Investigator 2019 - 2024
Addgene 705468 awarded by Addgene, Inc. Principal Investigator 2022 - 2023
Addgene 703836 awarded by Addgene, Inc. Principal Investigator 2022 - 2023

Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis awarded by National Cancer Institute Co-Investigator 2023 - 2028
Targeting lipid metabolism and diet in patients with locally advanced prostate cancer awarded by Prostate Cancer Foundation Co-Investigator 2023 - 2023
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis awarded by National Cancer Institute Co-Investigator 2018 - 2023
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Co-Investigator 2017 - 2023

BPTF-mediated gene regulation in prostate cancer awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2025

more ...

less ...

Background

education and training

M.D., Vanderbilt University School of Medicine 2007
Ph.D., Vanderbilt University School of Medicine 2005
A.B., Dartmouth College 1998

Contact

full name

Christopher Barbieri

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Christopher Barbieri Associate Professor of Urology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage